Needle-Free Injector Market Size, Share, Opportunities, And Trends By Type (Liquid-based Needle-free Injectors, Projectile-based Needle-free Injectors, Powder-based Needle-free Injectors), By Product (Fillable, Prefilled), By Technology (Jet-based Needle-free Injectors, Spring-based Needle-free Injectors, Microarray Patch Injectors, Others), By Usability (Disposable, Reusable), By Application (Vaccine Delivery, Insulin Delivery, Oncology, Pain Management, Dermatology, Others), By Delivery Site (Subcutaneous, Intramuscular, Intradermal), By End-user (Hospitals, Hospitals & Clinics, Home Care Settings, Research Laboratories, Others), And By Geography - Forecasts From 2024 To 2029

The needle-free injector market is anticipated to expand at a high CAGR over the forecast period.

A number of factors are contributing to the significant rise that the needle-free injector industry is seeing. First off, those who are uncomfortable getting shots or who are afraid of needles are increasingly in need of painless drug delivery systems. Additionally, the need for effective and user-friendly delivery methods is being driven by the rising global prevalence of chronic diseases that necessitate frequent medicine administration. Needle-free injectors lower the risk of needle-stick injuries and increase patient adherence to treatment plans by delivering medication via the skin without the need for a needle by using pressure technology. Furthermore, continuous technological developments—like the creation of more accurate and compact injectors—are driving market growth. The COVID-19 pandemic has also been a major factor in the adoption of needle-free injectors, especially in the delivery of vaccines.

Market Drivers:

• Rising demand for patient comfort is anticipated to boost the needle-free injector market.

The market for needle-free injectors is mostly driven by the growing requirement for patient comfort. Patients look out for painless drug administration techniques, particularly those who are sensitive to needles or have needle phobia. By distributing medication via the skin without the use of needles, needle-free injectors provide a solution and lessen the pain and anxiety associated with conventional injections. Better health results result from patients adhering to their treatment plans more closely because they feel more comfortable. As a result, the needle-free injector market is expanding due to the increased use of these devices by pharmaceutical firms and healthcare providers in response to the growing need for patient-centric solutions.

 The FDA recently authorized RyaltrisTM nasal spray from Glenmark as a new drug application (NDA) in January 2022 for the treatment of seasonal allergic rhinitis symptoms in adults and paediatric patients 12 years of age and older. The VP3 multidose device is being used to administer this medicine, according to a statement from Aptar Pharma. Combining an antihistamine (Olopatadine) with a steroid (Mometasone Furoate), RyaltrisTM is a prescription combination medication spray that is metered, fixed-dose, aqueous suspension that is used to treat nasal and ocular symptoms of seasonal allergic rhinitis. It makes use of the cutting-edge VP3 nasal spray from Aptar Pharma, which has a specially made decreased evaporation cap.

• Prevalence of chronic diseases is expected to boost the needle-free injector market.

The market for needle-free injectors is mostly driven by the prevalence of chronic diseases. Frequent medicine administration is becoming more and more necessary due to the development of illnesses, including diabetes, autoimmune disorders, and hormone shortages worldwide. Injectors without needles provide a painless substitute for conventional needles, improving patient comfort and treatment compliance. These gadgets make it simple for people to take care of their own drug needs, which eases the strain on healthcare systems and raises patient satisfaction levels. The necessity for needle-free injectors is anticipated to develop as the prevalence of chronic illnesses rises, propelling market expansion and technological innovation in drug delivery.

In 2021, PharmaJet®, a pioneer in needle-free injection technology, announced that Zydus Cadila, a partner, has obtained the Emergency Use Authorization (EUA) for ZyCoV-D, the world's first Plasmid DNA vaccine, from the Drug Controller General of India (DCGI). The PharmaJet Tropis® Needle-free Injection System is the only way to administer the ZyCoV-D vaccination.

• Technological advancements are anticipated to boost the needle-free injector market.

Innovations in technology are a major factor propelling the needle-free injector industry. Smaller, more accurate, and more effective injectors have been developed as a result of ongoing innovation, improving their use and suitability in a range of healthcare environments. Further enhancing patient convenience and treatment results, these developments have made it possible to integrate features like dose management, wireless connectivity, and smart functionality. Furthermore, continuous research and development endeavors concentrate on augmenting the safety, dependability, and adaptability of needle-free injection technology, propelling market advancement and acceptance by pharmaceutical businesses and healthcare providers in equal measure.

In June 2022, the makers of a needle-free in-home medication delivery platform, NovaXS Biotech Corp., announced a new version of their smart medication device for needle-free injectable therapy. In under 0.3 seconds, Telosis—a patent-pending technology—administers a narrow stream of medication without needing a needle and analyses injection data to empower users to make better health decisions.

Asia Pacific region is expected to grow significantly.

The market for needle-free injectors is expanding significantly in the Asia Pacific area. The rising incidence of chronic illnesses, rising healthcare costs, and growing accessibility to healthcare services are some factors propelling this region's market expansion. The use of needle-free injectors is also being accelerated by improvements in healthcare infrastructure, rising public knowledge of needle-free injection technologies, and supportive government measures. In addition, the COVID-19 pandemic has increased the requirement for needle-free injectors for the delivery of vaccines, which has aided in the market growth in Asia Pacific. The Asia-Pacific region offers significant prospects for needle-free injector market growth and innovation due to its sizable population base and growing healthcare requirements.

Market Restraints:

• The high initial cost of technology adoption can constrain the market for needle-free injectors.

An important obstacle facing the needle-free injector industry is the significant upfront costs associated with implementing this technology. Although needle-free injectors have several advantages, such as improved patient safety and comfort, certain healthcare facilities and physicians may find the initial cost of these devices to be exorbitant. Widespread adoption of needle-free injectors may also be hampered by reimbursement regulations and coverage restrictions, especially in areas with low reimbursement rates or little funding for healthcare.

Market Development:

• May 2023- PharmaJet® declared that it will assist the World Health Organization's (WHO) efforts to eradicate polio in Pakistan beginning in May 2023. For a supplemental immunization activity (SIA) campaign that will be carried out in two phases in the Southern districts of Khyber Pakhtunkhwa (KP) Province, located in the northwest of Pakistan, and in the Quetta Block, located in Northern Balochistan Province, close to the border between Pakistan and Afghanistan, PharmaJet is donating an additional 5 million syringes to the World Health Organisation. The PharmaJet Tropis Precision Delivery SystemTM (PDS) was chosen because of its enhanced benefits for immunization coverage, simplicity of training, and demonstrated cost savings.
• May 2022- Gerresheimer AG and Portal Instruments formed a strategic alliance in May 2022 to treat patients with chronic illnesses using a novel needle-free medication administration system. The companies are working together to provide patients with a painless injection experience.

Market Segmentation

• By Type:
  • Liquid-based Needle-free Injectors
  • Projectile-based Needle-free Injectors
  • Powder-based Needle-free Injectors
• By Product:
  • Fillable
  • Prefilled
• By Technology:
  • Jet-based Needle-free Injectors
  • Spring-based Needle-free Injectors
  • Microarray Patch Injectors
  • Others
• By Usability:
  • Disposable
  • Reusable
• By Application:
  • Vaccine Delivery
  • Insulin Delivery
  • Oncology
  • Pain Management
  • Dermatology
  • Others
• By Delivery Site:
  • Subcutaneous
  • Intramuscular
  • Intradermal
• By End-user:
  • Hospitals
  • Hospitals & Clinics
  • Home Care Settings
  • Research Laboratories
  • Others
• By Geography:
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others